Monoclonal antibody PAL-M1 recognizes the transferrin receptor and is a progression marker in melanocytic lesions.
Monoclonal antibody PAL-M1, which was selected to discriminate between nevocellular nevi and cutaneous melanomas, has not been characterized until now. Here we show that PAL-M1 is directed against the transferrin receptor (CD71). The molecules precipitated by PAL-M1 and by anti-transferrin receptor antibodies OKT9 and 5E9 from various human tumor cell lines (melanoma, hepatoma, and lymphoma) show identical characteristics on SDS-PAGE. PAL-M1 also specifically recognized mouse L cells expressing the human transferrin receptor gene. Competition experiments demonstrated that PAL-M1 and OKT9 recognize the same or a spatially close determinant. Immunohistochemical staining of a large series of melanocytic lesions indicates that the transferrin receptor can be considered as a progression antigen in this type of lesion.
van Muijen
G N
GN
Department of Pathology, Nijmegen University Cancer Center, University Hospital Nijmegen, The Netherlands.
Ruiter
D J
DJ
Hoefakker
S
S
Johnson
J P
JP
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm / Q000276:immunology; D006801:Humans; D008544:Melanocytes / Q000378:metabolism* / Q000502:physiology; D008545:Melanoma / Q000378:metabolism; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins / Q000276:immunology / Q000378:metabolism*; D011233:Precipitin Tests; D011990:Receptors, Transferrin / Q000276:immunology / Q000378:metabolism*; D014407:Tumor Cells, Cultured / Q000378:metabolism
D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D058950:Melanoma-Specific Antigens; D009363:Neoplasm Proteins; D011990:Receptors, Transferrin